Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Celldex Therapeutics (CLDX) Accounts Payables (2016 - 2025)

Historic Accounts Payables for Celldex Therapeutics (CLDX) over the last 16 years, with Q3 2025 value amounting to $4.3 million.

  • Celldex Therapeutics' Accounts Payables rose 28303.41% to $4.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.3 million, marking a year-over-year increase of 28303.41%. This contributed to the annual value of $3.3 million for FY2024, which is 655.41% down from last year.
  • Latest data reveals that Celldex Therapeutics reported Accounts Payables of $4.3 million as of Q3 2025, which was up 28303.41% from $2.1 million recorded in Q2 2025.
  • Over the past 5 years, Celldex Therapeutics' Accounts Payables peaked at $4.3 million during Q3 2025, and registered a low of $685000.0 during Q2 2021.
  • Its 5-year average for Accounts Payables is $2.3 million, with a median of $2.3 million in 2022.
  • The largest annual percentage gain for Celldex Therapeutics' Accounts Payables in the last 5 years was 33155.51% (2024), contrasted with its biggest fall of 6893.47% (2024).
  • Over the past 5 years, Celldex Therapeutics' Accounts Payables (Quarter) stood at $1.2 million in 2021, then skyrocketed by 171.99% to $3.3 million in 2022, then increased by 4.61% to $3.5 million in 2023, then fell by 6.55% to $3.3 million in 2024, then skyrocketed by 30.69% to $4.3 million in 2025.
  • Its Accounts Payables was $4.3 million in Q3 2025, compared to $2.1 million in Q2 2025 and $3.4 million in Q1 2025.